NSUN5 Antibody

What applications are NSUN5 antibodies validated for in research settings?

NSUN5 antibodies have been extensively validated for multiple applications in molecular and cellular biology research. Based on current validation data, these antibodies are suitable for:

• Western Blot (WB): Typically used at dilutions of 1:500-1:3000, with optimal concentration around 0.4 μg/ml

• Immunohistochemistry (IHC): Recommended dilutions range from 1:50-1:500

• Immunocytochemistry/Immunofluorescence (ICC/IF): Effective at concentrations of 1-4 μg/ml or dilutions of 1:250-1:1000

• RNA Immunoprecipitation (RIP): Validated for NSUN5-RNA interaction studies

• ELISA: Various formats including quantitative sandwich ELISA

For immunohistochemistry applications using paraffin-embedded tissues, antigen retrieval is typically recommended using TE buffer at pH 9.0, although citrate buffer at pH 6.0 can serve as an alternative .

What is the optimal sample preparation protocol for detecting NSUN5 by Western blot?

For optimal Western blot detection of NSUN5:

• Lysate preparation: Total cell lysates from human cells (e.g., HeLa, A549, U251) provide strong detection signals

• Expected molecular weight: NSUN5 typically appears at 47-52 kDa, with the most common observed size being 47 kDa

• Loading amount: 20-40 μg of total protein per lane is generally sufficient

• Blocking conditions: 5% non-fat milk in TBST for 1 hour at room temperature

• Primary antibody incubation: Overnight at 4°C using dilutions specified above

• Detection methods: Both chemiluminescence and fluorescence-based systems are suitable

Human kidney, placenta, and cancer cell lines (particularly HeLa and A549) serve as positive controls for NSUN5 expression validation .

How should NSUN5 antibodies be stored to maintain optimal activity?

For maximum stability and activity retention:

• Store concentrated antibody stocks at -20°C

• For short-term storage (up to 2 weeks), 4°C is acceptable

• Avoid repeated freeze-thaw cycles by preparing single-use aliquots

• Most commercial NSUN5 antibodies are provided in PBS with 0.02% sodium azide and 40-50% glycerol at pH 7.2-7.3

• Do not dilute the stock antibody until ready for use

• Working dilutions should be prepared fresh for each experiment

Notable stability data indicates most antibodies maintain activity for at least one year when stored properly at -20°C .

Which fixation and permeabilization methods work best for NSUN5 immunofluorescence staining?

For optimal immunofluorescence detection of NSUN5:

• Fixation: 4% paraformaldehyde (PFA) for 15-20 minutes at room temperature

• Permeabilization: 0.1-0.5% Triton X-100 for 5-10 minutes

• Blocking: 1-5% BSA or normal serum in PBS for 30-60 minutes

• Antibody dilution: Use concentrations of 1-4 μg/ml or dilutions of 1:250-1:1000

• Nuclear counterstaining: DAPI works well as NSUN5 shows primarily nucleolar localization

Published studies indicate strong nuclear and nucleolar staining patterns in cells like A-431, HeLa, and A172 . The subcellular localization data is consistent with NSUN5's function in ribosomal RNA modification.

How do researchers validate NSUN5 antibody specificity for experimental systems?

Multiple validation approaches should be employed to ensure antibody specificity:

• Genetic validation:

  • CRISPR/Cas9 knockout cells show disappearance of the target band in Western blot

  • shRNA/siRNA knockdown shows proportional reduction in signal intensity

• Recombinant protein controls:

  • Overexpression systems using NSUN5-Myc-DDK tagged constructs

  • Blockade with immunizing peptide (if available)

• Cross-validation across techniques:

  • Consistent results across WB, IHC, and IF applications

  • Correlation between protein and mRNA expression data

• Orthogonal validation:

  • RNAseq correlation with protein expression levels

  • Use of multiple antibodies targeting different epitopes of NSUN5

For example, successful validation has been demonstrated using NSUN5 CRISPR knockout plasmids targeting exon II of the NSUN5 gene, with clones verified by Sanger sequencing and Western blotting .

What methodological approaches are optimal for investigating NSUN5's role in RNA methylation?

To study NSUN5's RNA methyltransferase function:

• RNA methylation detection methods:

  • m5C dot-blot assays using specific antibodies

  • Methylated RNA immunoprecipitation sequencing (MeRIP-seq)

  • Liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS)

  • Bisulfite sequencing for site-specific m5C mapping

• Functional domain investigation:

  • Site-directed mutagenesis of catalytic domains (e.g., C308, C359)

  • RNA electrophoretic mobility shift assays (REMSA)

  • In vitro methylation assays using recombinant NSUN5 protein

• Target identification strategies:

  • RNA immunoprecipitation (RIP) followed by sequencing

  • Crosslinking and immunoprecipitation (CLIP) techniques

  • 5-azacytidine-mediated covalent RNA-protein complex isolation

Research has identified C3782 of 28S rRNA as a key methylation target of NSUN5, and methodological approaches combining genomic and proteomic techniques have revealed new targets such as CTNNB1 chromatin-associated RNA and ZBED3 mRNA .

How can NSUN5 knockdown and overexpression systems be optimized for functional studies?

For effective manipulation of NSUN5 expression:

• Knockdown approaches:

  • Lentivirus-mediated shRNA (typically requires 2+ constructs targeting different regions)

  • Recommended controls: scrambled shRNA (shControl)

  • Verification: Western blot analysis 72-96 hours post-transduction

• Overexpression strategies:

  • Lentiviral vectors (e.g., pLenti-NSUN5-Myc-DDK)

  • Appropriate controls: empty vector transduction

  • Selection method: puromycin resistance (2 μg/ml for ~10 days)

• CRISPR/Cas9 knockout methodology:

  • Guide RNA design targeting exon II (see example sequences)

  • Transfection method: Lipofectamine 2000 with 5 μg plasmid

  • Selection: FACS sorting for reporter gene (e.g., mCherry)

  • Validation: Single-cell expansion followed by Sanger sequencing and Western blot

The timing of experiments after genetic manipulation requires optimization, with functional effects typically observable 5-7 days post-manipulation in most cell systems.

NSUN5 expression has significant clinical correlations:

These clinical correlations suggest NSUN5 as both a potential prognostic marker and therapeutic target, particularly in glioblastoma and hepatocellular carcinoma.

What is the relationship between NSUN5 and RNA 5-methylcytosine (m5C) modification in cancer progression?

The relationship between NSUN5 and m5C modification has several mechanistic dimensions:

• NSUN5 as an m5C writer enzyme:

  • Deposits m5C primarily on C3782 of 28S rRNA

  • Recently discovered to methylate mRNAs and chromatin-associated RNAs (caRNAs)

  • Utilizes S-adenosyl-L-methionine as methyl donor

• Cancer-specific modification patterns:

  • In HCC: NSUN5-mediated m5C modification of ZBED3 mRNA activates Wnt/β-catenin signaling

  • In glioblastoma: NSUN5 modifies CTNNB1 caRNA, which is subsequently converted to 5hmC by TET2

  • Modified RNAs show altered stability and translation efficiency

• Methodological approaches to study this relationship:

  • MeRIP-seq and RIP-seq for global target identification

  • Site-specific mutagenesis of catalytic residues (C308, C359)

  • m5C dot-blot assays and LCMS/MS for quantification

  • In vitro methylation assays with recombinant proteins

Research indicates that the NSUN5/TET2/RBFOX2 signaling axis represents a general mechanism controlling the metabolism of m5C-modified RNA, with implications for cancer progression and therapeutic intervention .

How do researchers distinguish between NSUN5's role in ribosomal RNA modification versus other RNA targets?

Distinguishing between NSUN5's diverse RNA targets requires specialized approaches:

• Ribosomal RNA-specific investigations:

  • Nucleolar fractionation to isolate rRNA

  • Specific ribosomal RNA methylation analysis using bisulfite sequencing

  • Polysome profiling to assess translational effects

  • Creation of NSUN5-△120 mutant (deleted amino acids 1-120) that localizes outside the nucleolus

• mRNA and caRNA target identification:

  • RNA immunoprecipitation with NSUN5 antibodies

  • 5-azacytidine-mediated covalent trapping

  • RNA probe binding experiments (REMSA) with site-specific mutations

  • Compartment-specific RNA isolation (chromatin-associated, cytoplasmic, nuclear)

• Functional separation strategies:

  • NSUN5-GR fusion protein with triamcinolone acetonide (TA) induction for controlled nuclear translocation

  • Domain-specific mutations that affect specific RNA binding capabilities

  • Rescue experiments with wild-type versus mutant NSUN5

For example, studies have demonstrated that NSUN5-△120 loses its ability to modify 28S rRNA but maintains the capacity to regulate β-catenin expression, indicating separate functional mechanisms beyond its canonical role in ribosomal RNA modification .

What technical challenges exist in studying NSUN5 in neurodevelopmental contexts and Williams-Beuren Syndrome?

NSUN5 research in neurodevelopmental contexts faces several technical challenges:

• Model system limitations:

  • NSUN5 is one of 25 heterozygously deleted genes in Williams-Beuren Syndrome (WBS)

  • Isolating NSUN5-specific effects from other deleted genes requires specialized models

  • Nsun5 knockout mice show cognitive deficits but complex phenotypes

• Tissue-specific expression analysis:

  • Brain region-specific antibody validation for IHC/IF

  • Need for optimized fixation protocols for neural tissues

  • Integration with developmental timing considerations

• Methodological approaches:

  • Single-cell analysis of NSUN5 expression in neural populations

  • Conditional and inducible knockout systems for temporal control

  • Integration of behavioral phenotyping with molecular analysis

• Technical considerations:

  • Low endogenous expression in some neural cell types

  • Challenges in distinguishing NSUN5 from other NSUN family members

  • Need for developmental stage-specific controls

Recent studies suggest that NSUN5 is required for corpus callosum and cerebral cortex development, highlighting the importance of optimized detection methods in neurodevelopmental research contexts .

What controls and validation methods are essential when using NSUN5 antibodies in chromatin immunoprecipitation studies?

For chromatin immunoprecipitation (ChIP) studies investigating NSUN5:

• Essential controls:

  • Input chromatin (typically 1-10% of starting material)

  • IgG control from the same species as the NSUN5 antibody

  • Positive control regions (known binding sites)

  • Negative control regions (non-binding sites)

  • NSUN5 knockdown/knockout controls to validate specificity

• Antibody validation requirements:

  • Documentation of specificity through Western blot

  • Prior successful use in immunoprecipitation applications

  • Epitope accessibility considerations in fixed chromatin

  • Batch-to-batch consistency testing

• Technical considerations:

  • Crosslinking optimization (1% formaldehyde for 10 minutes is standard)

  • Sonication parameters for optimal chromatin fragmentation (200-500 bp)

  • Antibody concentration optimization (typically 2-5 μg per reaction)

  • Washing stringency adjustments based on signal-to-noise ratio

• Advanced validation approaches:

  • Sequential ChIP (Re-ChIP) to confirm co-occupancy with interacting factors

  • ChIP-seq confirmation of genome-wide binding patterns

  • Integration with RNA-binding data (ChIRP, CHART, etc.)

Recent studies demonstrate that NSUN5 recruits TET2 and RBFOX2 to chromatin for RNA modification and metabolism, highlighting the importance of properly controlled ChIP studies in understanding NSUN5's chromatin-associated functions .

How can researchers troubleshoot weak or nonspecific signals when using NSUN5 antibodies?

When encountering detection issues with NSUN5 antibodies:

• Weak signal troubleshooting:

  • Increase antibody concentration (within recommended ranges)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Optimize protein loading (40-60 μg for Western blot)

  • Use enhanced sensitivity detection systems (e.g., Super Signal West Femto)

  • Consider antigen retrieval optimization for IHC/IF (test both citrate and TE buffers)

• Nonspecific signal resolution:

  • Increase blocking stringency (5% BSA instead of milk)

  • Add 0.1-0.5% Tween-20 to antibody dilution buffer

  • Perform additional washes with higher salt concentration

  • Test multiple antibody clones targeting different epitopes

  • Use monoclonal antibodies for higher specificity

• Technical adjustments:

  • Fresh sample preparation to minimize protein degradation

  • Inclusion of protease inhibitors in lysis buffers

  • Titration of antibody concentration using control samples

  • Reduction of background through filtering or pre-absorption

• Validation approaches:

  • Parallel testing of multiple NSUN5 antibodies

  • Inclusion of positive control samples (HeLa or A549 cells)

  • NSUN5 knockdown controls to confirm band specificity

What recommendations exist for optimizing NSUN5 antibody use in multiplexed immunofluorescence studies?

For successful multiplexed detection with NSUN5 antibodies:

• Antibody compatibility planning:

  • Select primary antibodies from different host species

  • If using multiple rabbit antibodies, consider sequential staining with direct labeling

  • Test for cross-reactivity between secondary antibodies

  • Validate spectral separation of fluorophores

• Protocol optimizations:

  • Test antibodies individually before multiplexing

  • Optimize concentration of each antibody separately

  • Consider tyramide signal amplification for weak signals

  • Implement appropriate blocking between sequential staining steps

• Controls for multiplexed detection:

  • Single-color controls for spillover compensation

  • Fluorescence-minus-one (FMO) controls

  • Secondary-only controls to assess background

• Technical considerations:

  • NSUN5 shows primarily nuclear/nucleolar localization, making it compatible with cytoplasmic markers

  • Optimal fixation with 4% PFA followed by Triton X-100 permeabilization

  • Test order of antibody application (typically most dilute first)

  • Consider spectral imaging for closely overlapping signals

Published immunofluorescence studies demonstrate successful co-staining of NSUN5 with nuclear markers, making it suitable for studies examining nuclear organization and function .

How does fixation method affect NSUN5 epitope accessibility in immunohistochemistry applications?

Fixation significantly impacts NSUN5 detection in tissues:

• Formalin fixation effects:

  • Standard 10% neutral buffered formalin may mask NSUN5 epitopes

  • Epitope retrieval is critically important (heat-induced epitope retrieval)

  • TE buffer (pH 9.0) is generally more effective than citrate buffer (pH 6.0)

  • Retrieval time optimization (15-30 minutes) is recommended

• Alternative fixation approaches:

  • Paraformaldehyde (4%) offers gentler fixation with better epitope preservation

  • Zinc-based fixatives may improve detection of certain epitopes

  • Methanol fixation can enhance nuclear protein detection but may distort morphology

• Tissue-specific considerations:

  • Brain tissues may require shorter fixation times

  • Highly vascularized tissues may need longer fixation

  • Decalcification procedures for bone require special optimization

• Technical recommendations:

  • Start with standardized antigen retrieval protocols

  • Test multiple retrieval methods on the same tissue

  • Include positive control tissues (placenta, kidney)

  • Perform titration studies to optimize antibody dilution for each fixation method

Research indicates that proper fixation and antigen retrieval are essential for accurate detection of NSUN5 in various tissues, with successful staining reported in human placenta and cancer tissues .

What emerging methodologies are being developed for studying NSUN5-mediated RNA modifications?

Several cutting-edge approaches are advancing NSUN5 research:

• Single-molecule RNA modification detection:

  • Nanopore sequencing for direct detection of m5C modifications

  • Single-molecule real-time (SMRT) sequencing approaches

  • Fluorescence resonance energy transfer (FRET)-based detection systems

• Spatial transcriptomics integration:

  • In situ sequencing techniques to map NSUN5-modified RNAs

  • Spatial resolution of m5C modifications in different cellular compartments

  • Integration with protein localization data (immunofluorescence)

• RNA modification dynamics:

  • Time-resolved RNA modification mapping using metabolic labeling

  • Studies of m5C to 5hmC conversion kinetics via TET enzymes

  • RNA modification-specific CLIP techniques

• Computational prediction tools:

  • Machine learning algorithms to predict NSUN5 target sites

  • Integration of RNA secondary structure information

  • Systems biology approaches to model NSUN5-dependent RNA networks

These emerging methodologies will help elucidate the temporal and spatial dynamics of NSUN5-mediated RNA modifications and their functional consequences in normal and disease states.

How might NSUN5 research inform potential therapeutic approaches in cancer?

NSUN5-directed therapeutic strategies show promising potential:

• Direct targeting approaches:

  • Small molecule inhibitors of NSUN5 methyltransferase activity

  • Antisense oligonucleotides or siRNAs for expression modulation

  • Protein degradation approaches (PROTACs, molecular glues)

• Pathway-based strategies:

  • Combinations targeting NSUN5 and CD47/SIRPα pathway

  • DNMT inhibitors (e.g., decitabine) to restore NSUN5 expression

  • IDH1-R132H mutant targeting in combination with NSUN5 modulation

• Biomarker applications:

  • NSUN5 expression as predictive biomarker for treatment response

  • m5C RNA modification patterns as diagnostic indicators

  • Correlation with immune microenvironment for immunotherapy selection

• Cancer-specific considerations:

  • Glioblastoma: NSUN5 inhibition increases temozolomide sensitivity

  • Hepatocellular carcinoma: NSUN5/Wnt/β-catenin pathway targeting

  • Context-dependent approaches based on cancer subtype

Recent research demonstrates that pharmacological blockade of DNA methylation or IDH1-R132H mutant and CD47/SIRPα signaling synergistically enhances TAM-based phagocytosis and glioma elimination in vivo, highlighting the translational potential of NSUN5-targeted approaches .